Covaxin only vaccine with efficacy data from phase III trials against delta variant at 65.2%

Covaxin only vaccine with efficacy data from phase III trials against delta variant at 65.2%

Efficacy data shows 63.6% protection against asymptomatic COVID-19; 65.2% protection against Delta variant; and 70.8 % protection against all variants of COVID19 virus.

Hyderabad: Hyderabad-based Bharat Biotech on Friday cited Lancet peer-review which confirmed the efficacy analysis of Bharat Biotech’s Covaxin.

As per phase-three clinical trials data, Covaxin demonstrates 77.8 per cent efficacy against symptomatic COVID-19. “COVAXIN is the only COVID-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the delta variant at 65.2 per cent,” the official statement by Bharat Biotech said, citing the Lancet study.

“Efficacy data demonstrates 63.6 per cent protection against asymptomatic COVID-19, 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta and 70.8 per cent protection against all variants of SARS-CoV-2 virus,” Bharat Biotech added.

“Efficacy analysis demonstrates Covaxin to be 77.8 per cent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group,” said the company’s statement.

Further, it said that Covaxin will be 93.4 per cent effective against severe symptomatic COVID-19.

“Safety analysis demonstrates adverse events reported were similar to placebo, with 12 per cent of subjects experiencing commonly known side effects and less than 0.5 per cent of subjects experiencing serious adverse events,” it said.

Dr Krishna Ella, Chairman and Managing Director (CMD) of Bharat Biotech said, “The data from our product development and clinical trials have been published in 10 peer-reviewed journals, making Covaxin one of the most highly published COVID-19 vaccines in the world,” he said.

READ ALSO :  WTC final: Everything you need to know ahead of historic clash between India and New Zealand

“I am delighted to see that the phase III efficacy data has also been published in the Lancet. This itself speaks high about the strong position of Covaxin amongst other global front-runners COVID-19 vaccines,” Dr Balram Bhargava, Director General, Indian Council of Medical Research (ICMR) said.

first published:Nov. 12, 2021, 9:47 a.m.

Source link